HRTX
What one share of Heron Therapeutics, Inc. /De/ holds
Pharmaceutical Preparations
We are a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.
Heron Therapeutics, Inc. /De/’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.93 |
|---|---|
| Profit | −$0.21 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.07 |
| Cash and investments | $0.11 |
| Debt | $0.18 |
| Book value | $0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.03 | −$4.57 | $0.08 | −$3.62 | — | −$0.54 |
| 2017 | $0.57 | −$3.65 | $0.05 | −$3.20 | — | $2.03 |
| 2018 | $1.06 | −$2.44 | $0.13 | −$2.75 | — | $4.74 |
| 2019 | $1.78 | −$2.50 | $0.09 | −$1.61 | — | $4.47 |
| 2020 | $0.98 | −$2.50 | $0.08 | −$2.11 | — | $2.59 |
| 2021 | $0.88 | −$2.24 | $0.03 | −$2.10 | — | $0.76 |
| 2022 | $0.99 | −$1.67 | $0.02 | −$1.37 | — | $0.11 |
| 2023 | $0.92 | −$0.80 | $0.01 | −$0.44 | — | −$0.23 |
| 2024 | $0.95 | −$0.09 | $0.01 | −$0.16 | — | −$0.22 |
| 2025 | $0.93 | −$0.12 | $0.00 | −$0.17 | — | $0.08 |